Clinicopathological features, risk and survival in lung cancer survivors with therapy-related acute myeloid leukaemia
- PDF / 875,769 Bytes
- 9 Pages / 595.276 x 790.866 pts Page_size
- 65 Downloads / 161 Views
RESEARCH ARTICLE
Open Access
Clinicopathological features, risk and survival in lung cancer survivors with therapy-related acute myeloid leukaemia Huabin Wang1, Yin Yin2, Ru Wang3, Junbin Huang1, Hongman Xue1, Yucai Cheng1, Lidan Zhang1 and Chun Chen1*
Abstract Background: A secondary malignancy is the most serious complication in lung cancer (LC) survivors. This study aimed to evaluate the clinicopathological features, predictable risk factors and survival of patients with LC who developed therapy-related acute myeloid leukaemia (t-AML). Methods: Patients from the Surveillance, Epidemiology, and End Results (SEER) database diagnosed with t-AML after LC between 1975 and 2015 were included. Standardized incidence ratios (SIRs) were used to perform multiple primary analyses. The risk of t-AML development among LC patients was assessed using a logistic regression model. Kaplan–Meier analysis was used to construct overall survival (OS) curves. Cox regression was used to assess the influence of various prognostic factors. Results: A total of 104 patients with t-AML after LC-targeting chemotherapy were included. The median latency period to the development of t-AML was 35.5 months. The calculated SIR of t-AML was 4.00. Chemoradiotherapy, small cell lung cancer (SCLC), or localized/regional-stage LC was a risk factor for the development of t-AML. The median OS was only 1 month, and those younger than 65 years were predicted to have a better OS time. Conclusions: t-AML is a rare but serious late complication in LC patients and is associated with a poor prognosis. It is necessary to carry out long-term follow-up and screen for t-AML in LC patients, especially among those undergoing both radiotherapy and chemotherapy, with SCLC or with localized/regional-stage LC. Keywords: Therapy-related acute myeloid leukaemia, Lung cancer, Incidence risk, Survival analysis, SEER database
Background Among cancers, lung cancer (LC) has the highest incidence and mortality rates worldwide. The estimated number of new cases of LC in the United States in 2019 was 228,150, and the estimated number of deaths was 142,670 [1]. The poor prognosis of LC is related to many factors, among which the occurrence of a secondary malignant tumour is a great obstacle for a disease-free status. * Correspondence: [email protected] 1 Pediatric Blood Center, the Seventh Affiliated Hospital of Sun Yat-sen University, 628 Zhenyuan Road, Guangming, Shenzhen, Guangdong 518107, P.R. China Full list of author information is available at the end of the article
The development of therapy-related acute myeloid leukaemia (t-AML) has always been considered a rare but highly serious complication of cytotoxic chemotherapy and radiotherapy [2]. It is estimated that t-AML after LC accounts for 5.9% of all t-AML and is the third most common malignant tumour after breast cancer and nonHodgkin’s lymphoma [3]. Recently, an increase in tAML incidence associated with increased use of adjuvant cancer treatment and a prolonged life span of cancer survivors has been reported [4,
Data Loading...
